Last Price
0.264
Today's Change
-0.011 (4.00%)
Day's Change
0.245 - 0.276
Trading Volume
1,099,861
Market Cap
4 Million
Shares Outstanding
17 Million
Avg Volume
1,177,001
Avg Price (50 Days)
0.49
Avg Price (200 Days)
2.05
PE Ratio
0.00
EPS
311.45
Earnings Announcement
11-Nov-2024
Previous Close
0.28
Open
0.27
Day's Range
0.245 - 0.2757
Year Range
0.216 - 128.0
Trading Volume
1,099,861
1 Day Change
-3.96%
5 Day Change
0.99%
1 Month Change
4.39%
3 Month Change
-75.99%
6 Month Change
-63.82%
Ytd Change
-95.91%
1 Year Change
-99.43%
3 Year Change
-99.99%
5 Year Change
-99.99%
10 Year Change
-99.99%
Max Change
-99.99%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.